Foresite Capital CEO Jim Tananbaum, M.D., says we’re in “one of the best biotech investment environments” of his multidecade ...

Ultragenyx and Mereo BioPharma have broken off another piece of brittle bone data, linking their drug candidate to sustained ...

GSK and Ochre Bio will work together in a $37.5 million partnership to pinpoint the drivers of liver disease. | GSK and Ochre ...

Shortly after announcing positive clinical trial data from its pulsed field ablation treatment for irregular heart rhythms, ...

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and ...

IQVIA hopes to help clinical trial sites rein in the number of different software systems they have to manage with a new ...

NodThera’s NLRP3 inhibitor has already proved its worth against Novo Nordisk’s blockbuster obesity drug in preclinical trials ...

The initial data drop assesses del-brax, a novel RNA therapeutic Avidity has dubbed an “antibody oligonucleotide conjugate,” ...

Vyaire Medical has put up the for-sale sign, as it files for Chapter 11 bankruptcy following dropping demand in the wake of ...

Amid an organizational reset, Bayer’s SVP and Global Head of Biotech Jens Vogel, Ph.D., has hit the exits after four years ...

Lokavant has released a new artificial intelligence solution it claims can help contract research organizations and sponsors ...

Johnson & Johnson Executive Vice President and Chief External Innovation and Medical Officer William Hait, M.D., Ph.D., will ...